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Abstract
AIM: To review the current literature for the specific 
clinical characteristics of inflammatory bowel disease 
(IBD) associated with primary sclerosing cholangitis 
(PSC).
METHODS: A systematical review for clinical chara-
cteristics of IBD in PSC was performed by conducting 
a broad search for “primary sclerosing cholangitis” 
in Pubmed. “Clinical characteristics” were specified 
into five predefined subthemes: epidemiology of 
IBD in PSC, characteristics of IBD in PSC (i.e. , 
location, disease behavior), risk of colorectal cancer 
development, IBD recurrence and de novo  disease 
after liver transplantation for PSC, and safety and 
complications after proctocolectomy with ileal pouch-
anal anastomosis. Papers were selected for inclusion 
based on their relevance to the subthemes, and were 
reviewed by two independent reviewers. Only full 
papers relevant to PSC-IBD were included. Additionally 
the references of recent reviews for PSC (< 5 years 
old) were scrutinized for relevant articles.
RESULTS: Initial literature search for PSC yielded 4704 
results. After careful review 65 papers, comprising a 
total of 11406 PSC-IBD patients, were selected and 
divided according to subtheme. Four manuscripts 
overlapped and were included in two subthemes. 
Prevalence of IBD in PSC shows a large variance, 
ranging from 46.5% to 98.7% with ulcerative colitis (UC) 
being the most common type (> 75%). The highest 
IBD rates in PSC are found in papers reviewing both 
endoscopic and histological data for IBD diagnosis. 
Although IBD in PSC is found to be a quiescent disease, 
pancolitis occurs often, with rates varying from 35% 
to 95%. Both backwash ileitis and rectal sparing are 
observed infrequently. The development of dysplasia 
or colorectal carcinoma is increased in PSC-IBD; the 
cumulative 10 years risk varying between 0% and 
11%. Exacerbation of IBD is common after liver tran-
splantation for PSC and de novo  disease is seen in 
1.3% to 31.3% of PSC-IBD patients. The risk for 
development of pouchitis in PSC-IBD is found to be 
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IBD[1,8], several studies aimed to characterize the 
clinical course and features of concomitant IBD and its 
differences from conventional UC and CD[9-12]. These 
studies showed increasing evidence that PSC-IBD may 
represent a distinctive phenotype in addition to the 
established and defined phenotypes UC and CD[11]. 
The IBD in PSC is frequently reported as a pancolitis, 
relatively often with rectal sparing. Although colitis 
in PSC tends to follow a quiescent course, patients 
with PSC-IBD are found to have a relatively high risk 
of developing colorectal carcinoma compared to IBD 
patients without PSC[13]. However, while evidence for 
distinct PSC-IBD phenotype is increasing, its reported 
characteristics vary. In this systematic review of the 
literature we therefore aimed to describe the specific 
characteristics of the PSC-IBD phenotype based on 
the most recent literature. We reviewed prevalence of 
IBD in PSC, its phenotypic characteristics and the risk 
of development of colorectal malignancy. In addition 
we looked at IBD associated with PSC in relation to its 
clinical course or de novo presentation after orthotopic 
liver transplantation (OLT) and we reviewed the 
safety of proctocolectomy and incidence of pouchitis 
reported for PSC-IDB. Finally, we discussed the shared 
and non-shared genetic factors to further highlight 
the distinct nature of this phenotype. Insight into how 
PSC-IBD differs from general IBD, will help clinicians 
in the field of IBD in their approach for this specific 
group of patients. 
MATERIALS AND METHODS
We first defined relevant subthemes related to the 
subject of IBD in PSC based on clinical observations 
and recent literature. 
Themes of interest 
Epidemiology of IBD in PSC: reported incidence, 
methods of case ascertainment and geographical 
variation.
Phenotypic features of IBD in PSC: Disease locali-
zation, activity, and its association with backwash 
ileitis and rectal sparing.
Colorectal cancer risk in PSC-IBD: The incidence 
and risk in comparison with conventional IBD.
PSC-IBD in relation to liver transplantation: Disease 
behavior after OLT and the occurrence of de novo 
IBD.
Ileal pouch anal anastomosis in PSC-IBD: Safety 
of the procedure and pouch complications.
A broad literature search using the keyword 
“primary sclerosing cholangitis” was performed in 
Pubmed (http://www.ncbi.nlm.nih.gov/pubmed), 
de Vries AB et al . PSC-IBD: A systematic review of the clinical characteristics
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significant, affecting 13.8% to 90% of the patients after 
proctocolectomy with ileo anal-pouch anastomosis.
CONCLUSION: IBD in primary sclerosing cholangitis 
represents a distinct phenotype that differs from UC 
and Crohn’s disease and therefore requires specialized 
management.
Key words: Primary sclerosing cholangitis; Inflammatory 
bowel disease; Incidence; Clinical characteristics; Risk 
of colorectal carcinoma; Liver transplantation; Pouchitis
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Inflammatory bowel disease (IBD) in primary 
sclerosing cholangitis (PSC) is observed to have dif-
ferent characteristics in comparison with conventional 
IBD without PSC. Based on these differences a distinct 
phenotype of IBD is suspected. Existing literature 
was reviewed for clinical characteristics of IBD in 
PSC yielding 65 studies consisting of 11406 PSC-IBD 
patients. A large variation for reported characteristics 
was found, which seem to be related to case ascer-
tainment. This emphasizes the importance of full 
colonoscopy and biopsies to accurately diagnose 
IBD in PSC. Overall however, IBD in PSC shows large 
differences in comparison with conventional IBD, 
therefore representing a distinct phenotype.
de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive 
inflammatory bowel disease phenotype in primary sclerosing 
cholangitis. World J Gastroenterol 2015; 21(6): 1956-1971 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v21/i6/1956.htm  DOI: http://dx.doi.org/10.3748/wjg.v21.i6.1956
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic 
cholestatic liver disease characterized by inflammation 
and fibrosis of both the intrahepatic and extrahepatic 
bile ducts[1]. There is no curative therapy available and 
in most cases, PSC leads to liver cirrhosis and liver 
failure ultimately requiring liver transplantation[2,3]. In 
the United States and Western Europe, the reported 
incidence of PSC is 0.9 and 1.3 per 100.000/year, and 
the prevalence is 8.5 and 13.6 per 100000[4,5]. There is 
a strong relationship between PSC and inflammatory 
bowel disease (IBD). Approximately 50% to 80% 
of the patients with PSC are also diagnosed with 
IBD, finding ulcerative colitis (UC) in approximately 
80% of these cases and Crohn’s disease (CD) or 
unclassified IBD (IBD-U) in the remaining 20%[6]. In 
patients with IBD, PSC is found much less common. 
Approximately 2.4% to 7.5% of UC patients and 
3.4% of CD patients are diagnosed with PSC[7]. 
With the established relationship between PSC and 
an online database comprising more than 23 million 
citations for biomedical literature from mEDLINE, life 
sciences journals, and online books. relevant papers 
addressing the defined subthemes were selected 
based on title and abstract. Papers not found relevant 
by both reviewers (BdV and MJ) were excluded. 
When in disagreement, papers were discussed and 
included or excluded based on mutual agreement. 
We only included full papers relevant to PSC-IBD. 
Additionally the references of recent review papers 
(< 5 years) concerning PSC-IBD were scrutinized for 
relevant articles. Full papers of the selected abstracts 
were reviewed by BdV. references in manuscripts 
specifically assessing the IBD phenotype in PSC were 
hand-searched to identify other relevant papers.
RESULTS
The literature search on “PSC” yielded 4704 results. 
After reviewing titles and manuscript type (excluding 
reviews), a total of 781 papers were selected for 
assessment of their abstracts. After careful review, 
215 papers were selected and divided into a specific 
subtheme. The scrutinizing of references from re-
views and PSC-IBD manuscripts yielded another 
16 papers. After reading the full text, 65 papers, 
comprising a total of 11406 patients with PSC-IBD, 
were selected for the review (Figure 1). Criteria for 
study selection were study size, relevance to the 
subthemes, and specification of data (i.e., number 
of patients with backwash ileitis, localization of IBD). 
Four papers[11,14-16] overlapped, and were included in 
two subthemes. 
Epidemiology: reported incidence and prevalence of 
IBD in PSC
Literature search and evaluation of reviews yielded 
18 papers with a total of 6589 included PSC-IBD 
patients. Data concerning epidemiology of PSC and 
associated IBD are summarized in Table 1.
PSC is a rare disease with a reported incidence 
between 0.07 and 1.31 per 100000[4,17]. The pre-
valence of associated IBD ranged from 46.5%[17] to 
98.7%[18], with UC being the most common type 
(> 75%) in PSC-IBD (Table 1). CD in PSC-IBD is 
found in approximately 16% of PSC patients (range: 
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PubMed search 
“Primary sclerosing cholangitis”
n  = 4704
Potentially interesting 
based on title
n  = 781 
Papers selected based on 
title and abstract 
n  = 215
Selected for 
PSC-IBD subthemes 
n  = 231
Excluded on title and 
manuscript type
n  = 3923
Excluded on abstract
n  = 566
Additional papers 
from review references
n  = 16
Excluded n  = 166
Lack of data/non specific (n  = 162)
Not accessible online (n  = 4)
Phenotype
n  = 12 
(1 overlapping)
Epidemiology
n  = 18
CRC risk
n  = 22
(2 overlapping)
OLT




Figure 1  Flow chart paper inclusion: An overview of study selection for papers included in the present review. PSC: Primary sclerosing cholangitis; IBD: 
Inflammatory bowel disease; CRC: Colorectal cancer; OLT: Orthotopic liver transplantation.
de Vries AB et al . PSC-IBD: A systematic review of the clinical characteristics
case ascertainment in studying rare diseases. In this 
review, all but two of the selected studies concerning 
epidemiology reviewed cholangiography or mrCP 
imaging to confirm the PSC diagnosis. Endoscopic 
imaging was reviewed in ten (55.5%) studies, 
of which seven also reviewed histological data to 
ascertain the method of IBD diagnosis in the included 
patients (Table 1). In the remaining eight studies, the 
presence of IBD in PSC was established or excluded 
based on registry data, physician surveys, or notes 
in medical file without reviewing original endoscopy 
or histology. Combined study population of these 
groups consisted of 1446 (endoscopy and histology), 
453 (endoscopy only) and 7645 (no review of original 
endoscopy or histology) PSC patients respectively. 
The studies that used both endoscopic and histological 
confirmation for IBD diagnosis seem to show a higher 
median percentage of IBD in PSC when compared 
with studies that only used endoscopy or did not 
review diagnostic workup for IBD (Figure 2). 
Geographic variation IBD - PSC: Geographic va-
riation in the incidence of PSC and associated IBD has 
been reported, with highest rates found in Western 
Europe and North America (Table 1) and lower rates 
in Asia[23-25]. Several studies from Asia reported an 
incidence of IBD in PSC ranging between 20% and 
34%[24,26-28]. 
Key points: Approximately 70% of patients with PSC 
have associated IBD, predominantly UC. The highest 
rates of IBD in PSC were observed in papers using 
strict case ascertainment criteria. Large geographic 
differences in the incidence of PSC and associated 
2.4%[19]-24.8%[20]). IBD-U is the least common IBD-
type in PSC, seldom representing more than 5%. The 
actual percentages are expected to be even lower, 
as studies on IBD-U with and without associated PSC 
show that part of the initial IBD-U diagnosis is later 
re-classified as either UC or CD[15,21].
Varying IBD rates found in PSC: A recent large 
Dutch population-based study showed lower incidence 
rates for both PSC and PSC-IBD when compared 
with most other studies[22]. This emphasizes the 
importance of large multi-center studies with proper 
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Table 1  Epidemiology primary sclerosing cholangitis - inflammatory bowel disease  n  (%)
Ref. Country Period Incidence1 PSC Male Gender PSC-IBD PSC-UC PSC-CD PSC-IBD-U Diagnosis 
IBD
Rabinovitz et al[100], 1990 United States NA NA     66 NA     47 (71.2)     39 (83.0)       8 (17.0) 0   IBD2,3
Farrant et al[19], 1991 United Kingdom 1972-1989 NA   126     78 (61.9)     85 (67.5)     83 (97.6)     2 (2.4) NA IBD2
Schrumpf et al[18], 1994 Norway 1975-1989 NA     77     51 (66.2)     76 (98.7)     58 (76.3)     11 (14.5)   7 (9.2)   IBD2,3
Escorsell et al[17], 1994 Spain 1984-1988 0.07     43     26 (60.5)     20 (46.5)     19 (95.0)     1 (5.0) NA IBD4
Broomé et al[2], 1996 Sweden ? - 1992 NA   305   195 (63.9)   249 (81.6)   220 (88.4)   20 (8.0)   9 (3.6) IBD2
Boberg et al[4], 1998 Norway 1986-1995 1.31     17     12 (70.6)     12 (70.6)       9 (75.0)       2 (16.7)   1 (8.3) IBD4
Ponsioen et al[20], 2002 The Netherlands 1979-1999 NA   174   105 (60.3)   114 (65.5)     83 (72.8)     28 (24.6)   3 (2.6) IBD4
Bambha et al[5], 2003 United States 1976-2000 0.90     22     15 (68.3)     16 (72.7)     12 (75.0)       3 (18.8)   1 (5.0) IBD2
Kingham et al[101], 2004 United Kingdom 1984-2003 0.91     53     33 (62.3)     33 (62.3)     30 (90.9)       3 (19.1) 0 IBD4
Bergquist et al[102], 2005 Sweden 1984-1999 NA   145   100 (69.0)   126 (86.9)   107 (84.9)     19 (15.1) 0   IBD2,3
Tischendorf et al[103], 2007 Germany 1978-2004 NA   273   195 (71.4)   172 (63.0)   141 (82.0)     29 (16.9)   2 (1.2)   IBD2,3
Bergquist et al[104], 2007 Sweden 1984-2004 NA   246   165 (67.1)   195 (79.3)   166 (85.1)     21 (10.8)   8 (4.1)   IBD2,3
Kaplan et al[14], 2007 Canada 2000-2005 0.92     49     27 (55.1)     36 (73.5)     17 (47.2)     19 (52.8) 0   IBD2,3
Card et al[3], 2008 United Kingdom 1987-2002 0.41   223   141 (63.2)   108 (48.4)     67 (62.0)     13 (12.0)   28 (25.9) IBD4
Lindkvist et al[105], 2010 Sweden 1992-2005 1.22   199   142 (71.4)   152 (76.4)   129 (84.9)     17 (11.2)   5 (3.3) IBD4
Bowlus et al[106], 2010 United States 1995-2009 NA 6767 4475 (66.1) 4637 (68.5) 3067 (66.1) 1090 (23.5) 480 (10.4) IBD4
Toy et al[107], 2011 United States 2000-2006 0.41   169   101 (59.8)   109 (64.5)     95 (87.2)     13 (11.9)   1 (0.9) IBD4
Boonstra et al[22], 2013 The Netherlands 2000-2007 0.50   590   375 (63.6)   402 (68.1)   308 (76.6)     78 (19.4) 16 (4.0)   IBD2,3
1Incidence for PSC per 100000 people; 2IBD Endoscopic findings; 3IBD Histological findings (biopsies); 4IBD diagnosis not specified/medical records only. 













based on registry 
data or survey 


















Figure 2  Case ascertainment: A comparison of included primary 
sclerosing cholangitis - inflammatory bowel disease epidemiology studies 
based on case ascertainment. PSC: Primary sclerosing cholangitis; IBD: 
Inflammatory bowel disease.
de Vries AB et al . PSC-IBD: A systematic review of the clinical characteristics
IBD between east and west are reported.
Distinctive features of IBD in PSC
Frequently documented characteristics of IBD in 
PSC include a mild or quiescent disease course and 
a high rate of pancolitis[9,29,30]. The association with 
backwash ileitis and rectal sparing in PSC-IBD is also 
suggested, but less consistently. The present review 
included twelve studies (1217 patients with PSC-
IBD) describing features of IBD in PSC, which are 
summarized in Table 2. In seven (58.3%) studies a 
comparison with conventional IBD was made. 
Disease activity: Out of the twelve included studies, 
eight (66.6%) characterized the clinical course of 
IBD in PSC. All eight studies classified the IBD’s 
overall activity as mild[9,11,15,30-34]. Every included study 
reviewed endoscopic and histological data to confirm 
IBD diagnosis (Table 2). In addition, four studies 
also assessed histological severity of inflammation in 
different segments of the colon, none finding severe 
inflammation in PSC-IBD[31-34]. The majority of these 
studies found that prevalence for inflammation was 
highest in the right-sided colon and lowest toward 
the distal colon. Both Joo et al[31] and Sano et al[32] 
reported this was significantly different (0.019 and 
0.034 respectively) in matched IBD-controls, with 
histologically graded inflammation being highest 
in the proximal colon and lowest in the rectum for 
PSC-IBD. In accordance with these results, two 
studies[12,33] reported a significant predominance of 
right-sided inflammation in PSC-IBD observed during 
endoscopy.
Disease localization in PSC-IBD: Localization 
and extent of IBD were determined by endoscopy 
in the majority of studies (Table 2). Involvement 
of the whole colon is more common in PSC-IBD 
(35%[32]-95%[25], mean 64.7%) than in IBD controls 
(25%[35]-62%[9], mean 47.5%). Several authors have 
found these differences to be significant[11,12,25]. The 
reported rates of left sided colitis in PSC-IBD varies 
between studies (2.5%[12]-90.7%[15], mean 18.8%), 
but are lower than in IBD without concomitant 
PSC (20%[12]-86.7%[15], mean 39.6%). The overall 
reported occurrence of proctitis-only is low for 
PSC-IBD in most studies (1%[35]-5.5%[9], Table 2) 
and less common in comparison with IBD controls 
(5%[12]-38%[9]). 
Backwash ileitis: Backwash ileitis (BWI) is an 
inflammation of the ileum due to diminished ileocecal 
valve function in severe UC, allowing for retrograde 
flow of colonic content and inflammation of the 
ileum[36]. The reported rates of BWI found for PSC-UC 
range between 5.0%-42.9% (mean 16.7%). In UC 
without PSC involvement of the ileum is infrequent, 
with reported rates ranging from 2.5%[12] to 24%[15] 
(mean 12.3%, Table 2).
Rectal sparing: rectal sparing (rS) is described 
as rectal mucosa in UC or CD which is completely or 
partially spared from active or chronic inflammation 
in comparison to the more proximal colon[37]. The 
frequency of rS in PSC-IBD is specified in eight 
studies (Table 2). The reported incidence shows a 
large variation ranging from 5.6%[14] and 66.4%[33] 
(mean 30.9%) in PSC-IBD, compared with 1.6%[25] 
and 25%[31] (mean 9.9%) in IBD without PSC. 
PSC-CD: The localization of PSC-CD is specified in 
five studies[11,12,14], two of which focused on the PSC-
CD phenotype[38,39]. Colonic involvement in PSC-
CD is reported most often (36.8%[14]-82.1%[38] 
followed by involvement of both ileum and colon 
(21.8%[12]-57.9%[14]). Isolated ileal involvement is 
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Proctitis Leftsided Pancolitis Backwash Rectal Sparing Diagnosis 
IBD
IBD PSC-IBD IBD PSC-IBD IBD PSC-IBD IBD PSC-IBD IBD PSC-IBD
Olsson et al[9], 1991 1445   55 552 (38.2) 3 (5.5) NA NA 893 (61.8) 52 (94.5) NA NA NA NA IBD1,2
Loftus et al[11], 2005   142   71 NA NA NA NA 76 (53.5) 60 (84.5) 10 (7.0) 20 (28.2)  8 (5.6) 34 (47.9) IBD1,2
Kaplan et al[14], 2007       0   36 NA NA NA NA NA 17 (47.2) NA 4 (11.1) NA 2 (5.6) IBD1,2
Sokol et al[15], 2008   150   75 138 (92.0) 68 (90.7) 130 (86.7) 68 (90.7) 91 (60.7) 49 (65.3) 36 (24.0) 14 (18.7) 20 (13.3) 15 (20.0) IBD1,2
Joo et al[31], 2009     40   40 0 0 14 (35.0) 3 (7.5) 18 (45.0) 34 (85.0) 3 (7.5) 4 (10.0) 10 (25.0) 11 (27.5) IBD1,2
Sano et al[32], 2010     60   20 18 (30.0) 1 (5.0) 19 (31.7) 1 (5.0) 21 (35.0) 7 (35.0) NA NA NA NA IBD1,2
Ye et al[25], 2011     63   21 NA NA NA NA 35 (55.6) 20 (95.2) 2 (3.2) 9 (42.9) 1 (1.6) 8 (38.1) IBD1,2
Jørgensen et al[33], 2012       0 110 NA NA NA 3 (2.7) NA 60 (54.5) NA 17 (15.5) NA 73 (66.4) IBD1,2
O'toole et al[35], 2012 2649 103 209 (7.9) 1 (1.0) 649 (24.5) 23 (22.3) 663 (25.0) 56 (54.4) NA NA NA NA IBD1,2
Boonstra et al[12], 2012       0 380 NA 9 (2.4) NA 34 (8.9) NA 219 (57.6) NA NA NA NA IBD1,2
Boonstra et al[12], 20123     80   80  4 (5.0) 2 (2.5) 16 (20.0) 2 (2.5) 35 (43.8) 52 (65.0) 2 (2.5) 4 (5.0) 1 (1.3) 8 (10.0) IBD1,2
Schaeffer et al[34], 2013       0   97 NA 0 NA 17 (17.5) NA 42 (43.3) NA NA NA NA IBD1,2
Sinakos et al[30], 2013       0 129 NA NA NA 16 (12.4) NA 76 (58.9) NA 15 (11.6) NA 31 (24.0) IBD1,2
Mean 28.8% 13.4% 39.6% 18.8% 47.5% 64.7% 12.3% 16.7% 9.9% 30.9%
1IBD Endoscopic findings; 2IBD Histological findings (biopsies); 3Subgroup analysis. PSC: Primary sclerosing cholangitis; IBD: Inflammatory bowel disease; 
NA: Not available.
de Vries AB et al . PSC-IBD: A systematic review of the clinical characteristics
rare in PSC-CD (2%[39]-5%[12]). The rate of ileitis 
is similar or lower in PSC-CD compared with CD 
controls[12,38,39]. rectal sparing is not significantly 
increased in PSC-CD[12,38] and isolated upper gastro-
intestinal CD is reported in only two patients[15,39]. The 
disease activity in PSC-CD is characterized as similar 
or less active then in CD controls, with lower rates 
of stricturing and penetrating disease seen during 
endoscopy[12,38,39].
Key points: IBD associated with PSC is characterized 
by a quiescent course with a predominance for mild 
right-sided inflammation and a proximal- or pan-
colitis. Although less common than pancolitis, both 
backwash ileitis and rectal sparing are more often 
found in PSC-UC compared with UC. In addition, 
strictures and penetrating disease were found to be 
less common in PSC-CD than in CD without PSC.
Colorectal cancer risk in PSC-IBD
The increased risk of development of colorectal cancer 
(CrC) in IBD has been widely recognized for several 
decades[40-44]. Both disease extent and duration of 
IBD have been identified as factors associated with 
this increased cancer risk[41,43,44]. An additional risk for 
development of dysplasia and CrC in PSC-IBD was 
observed by several authors[45-48]. A total of twenty-
two studies assessing CrC risk in PSC-IBD were 
reviewed, comprising a total of 2936 patients with 
PSC-IBD (Table 3).
CRC incidence and location in PSC-IBD: The 
10-year cumulative risk for the development of 
colonic dysplasia and CrC in PSC-IBD is reported 
in five studies[45,49-52] and varies between 0%[49] and 
11%[50]. In these studies the data on dysplasia or 
CrC development for IBD without PSC is limited, 
showing a 10 year cumulative risk of approximately 
2%[45,50,51]. The observed percentage of included PSC-
IBD patients developing dysplasia and CrC shows 
large differences, ranging from 1.3%[53] to 66.7%[54]. 
For the IBD controls, these percentages vary from 
0.7%[55] to 30.1%[46]. The mean time interval between 
diagnosis of IBD and development of CrC in PSC-
IBD ranges between 12.2[49] and 20[56] years (Table 
3). In comparison, in IBD without PSC the mean 
interval varies between 17.5[50] and 44.4[15] years. 
The median age at which dysplasia or CrC presented 
itself was specified in three studies on PSC-IBD and in 
one study on IBD, being lower in the former (Table 3). 
For IBD the development of CrC in the recto-sigmoid 
has been described more common in UC whereas CD 
shows a more equal distribution between right sided 
and left sided colonic malignancy[57]. Dysplasia or CrC 
in PSC-IBD frequently develops in the proximal colon 
with reported rates varying between 28.6%[11] and 
100%[55]. For IBD a proximal development of CRC 
and dysplasia is found less common (0%[15]-50%[11], 
Table 3).
CRC in PSC-CD and PSC without IBD: Limited 
data is available on the risk of CrC development in 
PSC-CD patients as it is less prevalent, and often 
only represents a few cases within PSC-IBD cohorts. 
Furthermore, disease characteristics of IBD in PSC 
can make it difficult to distinguish between UC and 
CD, resulting in a change of diagnosis during follow-
up. A study by Lindström et al[38], which compared 
28 PSC-CD patients with 46 CD controls found an 
increased risk of CrC development in PSC-CD that 
was comparable to the risk in PSC-UC. In contrast, 
a study by Braden et al[58] found a lower risk in 
PSC-CD compared with PSC-UC by looking at CrC 
development in 166 PSC-IBD (35 PSC-CD) and 216 
IBD controls (102 CD). risk of CrC development in 
PSC patients without IBD was found to be low[22,29,48,52].
Key points: The development of dysplasia and CrC 
in PSC-IBD is increased and has predominance for 
right-sided localization in comparison to conventional 
IBD. Based on limited results, presentation of 
dysplasia or CrC in PSC-IBD at a younger age is 
suggested. It remains unclear whether the interval 
between IBD diagnosis and dysplasia or CrC deve-
lopment was shorter.
PSC-IBD in relation to liver transplantation
In PSC patients after orthotopic liver transplantation 
(OLT), IBD exacerbations and even development of de 
novo IBD have been reported by a number of studies, 
despite continuous use of immunosuppressive me-
dication[59-62]. To review IBD disease activity and de 
novo presentation in PSC-IBD after OLT, eight studies 
comprising 519 patients with PSC-IBD were included. 
Papers concerning both autoimmune hepatitis and 
PSC were scrutinized for PSC-IBD data only. An 
overview of the selected papers is presented in Table 
4.
IBD Exacerbations and de novo disease after 
OLT for PSC: Exacerbation of IBD after OLT is 
estimated to occur in 8.6%[63] to 51.5%[62] of the 
patients, whereas de novo IBD is seen less frequently, 
varying from 1.3%[64] to 31.3%[61] in patients tran-
splanted for PSC. Long term outcome for IBD in PSC 
is reported in seven studies, with colectomy rates 
after OLT varying from 4.3%[59] to 19.5%[65] (Table 
4). Treatment-refractory IBD as an indication for 
colectomy ranged from 0%[59] to 85.7%[60].
Key points: Approximately 32.6% of patients with 
PSC-IBD experience an exacerbation of IBD after 
their liver transplantation. In addition, approximately 
18.3% of patients develop de novo IBD after liver 
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during follow up was assessed in five studies, which 
all showed similar results (Table 5). Pouch failure was 
seen in 1.5%[71] to 16.1%[70] of the PSC-IBD patients 
and in 3.3%[16] to 11.2%[72] of the IBD patients after 
IPAA. Safety of proctocolectomy with IPAA in PSC-
IBD was discussed in three studies, with the majority 
describing it as a safe procedure[73,74].
Key points: Pouchitis after IPAA is more frequently 
found in PSC-IBD patients compared with IBD 
patients. rate of pouch failure seems similar for IBD 
patients with and without PSC. Although data are 
limited, proctocolectomy with IPAA is deemed safe in 
PSC-IBD patients by the majority of studies.
DISCUSSION
In this review we have characterized the clinical fea-
tures of IBD associated with PSC. In addition, we 
aimed to provide data to assist clinicians in the IBD 
field, to aid management for this specific group. PSC-
IBD can be said to represent a distinct phenotype 
that differs from both UC and CD.
The prevalence for IBD found in PSC is high, being 
present in approximately 70% of the cases, with 
a large variation found between studies. The most 
common type is UC which represents > 75% of IBD 
found in PSC, followed by the less common CD and 
infrequently seen IBD-U. In contrast, a relative high 
prevalence of CD was found in a study by Kaplan 
et al[14] reporting 38.8% CD in the total of included 
patients with PSC. As possible explanations the 
authors suggested an increasing trend of awareness 
of PSC in IBD other than UC and the high prevalence 
of CD found (1.5 times that of UC) in the province of 
Alberta, Canada. Geographic differences could explain 
the large variation found in IBD prevalence in PSC. 
We found a high prevalence of IBD in PSC patients 
(> 60%) in Europe and North America, compared 
with lower rates of approximately 30% IBD in PSC 
patients in Asia. In most studies from Asia on PSC-
IBD however, endoscopic and histological data were 
not specified for the IBD diagnosis, making case 
ascertainment unreliable. A more recent Japanese 
study[32] establishing IBD diagnosis in PSC based 
on both endoscopic and histological data, showed 
an IBD incidence of 68%, similar to the percentage 
found in studies from Europe and North America. 
Although these results were based on a small study 
population and need to be validated by future large 
multicenter studies, they do suggest that case 
ascertainment affects the prevalence of IBD found in 
PSC. To explore whether reported rates of IBD in PSC 
are influenced by method of case ascertainment, a 
comparison between included epidemiological studies 
was made. Strikingly, the highest rates of IBD in 
PSC were found in studies using the most stringent 
criteria, reviewing both endoscopic and histology 
data, to exclude or establish the presence of IBD 
in PSC. In addition, the lowest prevalence of IBD 
in PSC was reported in studies using registry data, 
physician surveys or notes in the medical file without 
reviewing original endoscopy or histology. These 
results are in accordance with the observation that 
IBD in PSC can be present without clinical signs and 
with normal endoscopic appearance[33,75], resulting 
in underdiagnosis[45]. This observation stresses the 
importance of histological diagnosis in PSC-IBD. In 
contrast, one of the largest PSC population-based 
studies to date, shows a relatively low rate of IBD in 
PSC patients (68.1%), while reviewing both histology 
and endoscopy[22]. Our findings can therefore 
not fully explain the large variation found in IBD 
prevalence in PSC, but they do stress the importance 
of full endoscopy combined with random biopsies to 
determine the presence of IBD in PSC patients.
The present review found that IBD in PSC patients 
is characterized by a mild disease activity, seldom 
showing severe inflammation. The prevalence of 
colonic inflammation follows a proximal to distal 
distribution, with most activity found in the cecum 
and ascending colon. A pancolitis is seen in > 60% 
of IBD associated with PSC. Isolated distal colon 
involvement in PSC-IBD is seen in < 20%, with 
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Table 4  Primary sclerosing cholangitis - inflammatory bowel disease and liver transplantation  n  (%)
Ref. n Pre-OLT Post-OLT
PSC only PSC-IBD Intact colon1 De novo  IBD Exacerbation Colectomy Refractory IBD Median follow-up (yr)
Dvorchik et al[65], 2002 192 0 192 169 (88.0) NA 22 (13.0) 33 (19.5) 22 (66.7)  5.93
Haagsma et al[59], 2003   48 25 (52.1) 23 (47.9)     23 (100.0)   6 (24.0)   9 (39.1) 1 (4.3) 0 7.2
Verdonk et al[88], 2006   60 15 (25.0) 45 (75.0)     45 (100.0)   3 (20.0) NA NA NA 6.1
Cholongitas et al[62], 20072   56 18 (32.1) 38 (67.9)   33 (68.8)   3 (16.6) 17 (51.5)   7 (16.7) 3 (42.9) 2.8
Moncrief et al[61], 2010   59 16 (27.1) 42 (71.2)   32 (76.2)   5 (31.3) 13 (40.6)   6 (18.8) 4 (66.7) 5.6
Joshi et al[60], 2011 110 36 (32.7) 74 (67.3)   65 (87.8)   6 (16.7) 33 (50.8)   7 (10.8) 6 (85.7)  6.53
Navaneethan et al[63], 2012   77 0 77   58 (75.3) NA 5 (8.6)   9 (15.5) 3 (33.3) 5.0
Mosli et al[64], 2013 105 77 (73.3) 28 (26.7)   24 (85.7) 1 (1.3)   6 (25.0) 2 (8.3) 0  7.33
1Patients with PSC-IBD and without proctocolectomy prior to OLT; 2Study population corrected for survival > 1 year after OLT (n = 56, 18 PSC only, 
33 PSC-IBD, 5 PSC-IBD with pre-OLT colectomy, extracted from paper); 3Mean instead of median. OLT: Orthotopic liver transplantation; PSC: Primary 
sclerosing cholangitis; IBD: Inflammatory bowel disease; NA: Not available.
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Finally, discrepancies in diagnosis of rS have been 
reported, showing rectal involvement in resected 
specimens despite frequently found rectal sparing 
in biopsies[37]. A comparison between rates of rS in 
PSC-IBD patients and rates found in IBD controls 
also yielded conflicting results. While all studies 
comparing rS incidence between PSC-IBD and IBD 
controls found higher rates in the former group, 
differences were significant in only two studies[11,25]. 
In contrast, Joo et al[31] found almost equal rates of 
rS in both UC and UC with associated PSC in their 
review of histological specimens. Both these results 
and the previously stated limitations regarding the 
diagnosis of rS, make it difficult to see rS as a 
distinct feature of the PSC-IBD phenotype. Diagnosis 
of true rS requires both endoscopic and histological 
absence of inflammation with the exclusion of recent 
(< 6 mo) local steroid therapy.
Based on limited results from small subgroup 
populations, we found that the characteristics of CD 
in PSC are similar to those found in UC associated 
with PSC. Disease activity is mild with an observed 
lower frequency of stricturing and penetrating disease 
compared with conventional CD. An isolated colitis is 
most common, being present in 55% of the patients 
with PSC-CD. Notably, the severity of PSC-CD may 
also be less, compared with PSC associated with UC. 
This was suggested by two studies[39,39,77] that found 
higher rates of small duct PSC in CD compared with 
PSC-UC, with one also finding a non-significant (P = 
0.06) trend for increased survival[39]. 
PSC as a third and separate risk factor for CrC 
in concomitant IBD was first proposed by Broomé 
et al[78] in 1992 and was subsequently confirmed 
by several authors[22,38,46]. Other studies, however, 
have questioned this finding. They found that PSC 
did not constitute an additional risk of CrC[11,29,79] 
and proposed that PSC-IBD characteristics, i.e., 
pancolitis and mild sub-clinical disease, facilitate 
the two previously mentioned risk factors for CrC 
development in IBD and explain the higher rates of 
CrC in PSC-IBD[11]. 
A comparison between the estimated risk of 
dysplasia and CrC development in PSC-IBD poses a 
challenge, as the use of statistical analyses and output 
parameters greatly varies between studies (Table 
3). The most common reported format for colonic 
dysplasia and CrC development is the cumulative 
10 year risk, which ranges from 0% to 11% for 
PSC-IBD. In all studies combined, development of 
dysplasia or CRC is observed in approximately 24% 
of patients with PSC and associated IBD. In contrast, 
in IBD controls the development of dysplasia or CrC 
is observed in 9% of the patients, with a reported 
estimated cumulative 10 years risk of 2%. In 
addition, a recent large French prospective study on 
neoplasia in IBD found an even lower rate of patients 
developing colonic neoplasia. In this study 0.3% of 
19486 patients developed high grade dysplasia or 
CrC[80]. 
The included studies on both IBD and PSC-IBD 
differed greatly with respect to reported rates of 
dysplasia and CrC development. These differences are 
likely caused by the retrospective nature of the studies 
and by differences between centers regarding referral 
bias. Furthermore, discrepancies in the definition of 
dysplasia were found. Some studies reported all types 
of dysplasia, including low grade dysplasia, whereas 
other studies only registered colorectal cancer. While 
the progression of low grade dysplasia to advanced 
neoplasia in IBD has been shown to be low[81,82], it is 
worth noting that an increased risk of progression in 
PSC-IBD has been observed[83] making its inclusion 
justifiable. Based on these results and by taking 
study limitations into account, an increased risk of 
development of dysplasia and CrC in PSC-IBD can 
be confirmed. Future studies would benefit from a 
standard statistical output parameter to determine the 
risk of development of CrC in PSC-IBD.
Apart from an increased risk of CrC, a shorter 
interval between diagnosis of IBD and development 
of CrC in PSC-IBD was also reported[47]. The 
combined mean interval between development of 
IBD and colonic dysplasia or CrC found in patients 
with PSC-IBD is 19 years compared with 26 years 
for IBD patients without PSC. The observed median 
interval however,  shows the opposite, with equal or 
even lower median intervals in IBD compared with 
PSC-IBD (Table 3). Although data on the age of both 
PSC-IBD patients and IBD patients without PSC at 
diagnosis of CrC were scarce, a lower median age 
at diagnosis of CrC was suggested for the former 
group. Based on these results, it is unclear whether 
the age of presentation and the interval between IBD 
diagnosis and development of large bowel neoplasia 
are lower in PSC-IBD compared with IBD. As both 
a younger age at CRC diagnosis and the efficacy of 
early surveillance in PSC-IBD have been confirmed 
and disputed[22,53], further studies are warranted.
As noted earlier, in PSC-IBD, a predisposition for 
development of right-sided colonic dysplasia and 
CrC has been observed[46,54,55,84]. While the reported 
percentages vary, a high predominance (> 60%) for 
dysplasia and CRC development in the proximal colon 
is confirmed by the majority of studies. The exact 
cause of increased dysplasia and CrC development 
in PSC-IBD however, remains unknown. A proposed 
mechanism is a cytotoxic and carcinogenic effect of 
secondary bile acids accumulating in the proximal 
colon due to defective small intestine reabsorption 
in cholestatic liver disease[85]. This assumption is 
strengthened by the association found between high 
concentrations of bile acids and the development of 
colon carcinoma in colitis[86].
The clinical course of IBD in PSC after liver tran-
splantation was both observed to stabilize[87] or 
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to worsen[88]. In all studies combined, we found 
that approximately 32% of patients with PSC-
IBD experience an exacerbation after OLT. For the 
development of de novo IBD after receiving a liver 
transplantation for PSC this was approximately 18%. 
These results are slightly lower than those presented 
in a recent review by Singh et al[89], who found IBD 
to worsen in a third of PSC-IBD patients after OLT. 
The different rates found for exacerbation and de 
novo presentation of IBD after liver transplantation 
for PSC have been contributed to the type of immuno-
suppressive medication, with lower rates reported 
for cyclosporin A and azathioprine compared with 
tacrolimus[59,88,90]. A proposed mechanism is the stron-
ger suppression of interleukin-2 production by T-cells 
in tacrolimus compared to cyclosporin A, resulting 
in an inability to activate a regulatory response[59]. 
A subsequent study by the same group was not 
able to find a drug specific effect for tacrolimus on 
regulatory T cells in noninflamed colon mucosa of 
OLT patients[91]. Although further (pathophysiological) 
studies are required, the use of cyclosporin and 
azathioprine over tacrolimus seems to have a more 
favorable outcome on IBD after OLT for PSC, and 
should therefore be considered.
An early study by Cangemi et al[92] showed no 
beneficial effect of proctocolectomy on the progression 
or development of complications in PSC patients. In 
addition, careful consideration was urged in choosing 
proctocolectomy with ileostomy as the treatment of 
choice for colonic disease in PSC-UC, as it resulted 
in frequent development of parastomal varices. The 
safety and complications of proctocolectomy with 
ileal pouch-anal anastomosis (IPAA) in PSC-IBD were 
infrequently reported. While two out of three studies 
described proctocolectomy to be safe in PSC-IBD 
finding no increased mortality, a significant number 
of patients experienced postoperative morbidity (29% 
and 39% respectively[73,74]). reported complications 
ranged from urinary tract and wound infections to 
bacterial cholangitis or hepatic decompensation. 
While peristomal varices are a common problem 
in ileostomy after proctocolectomy[93], none of the 
included studies demonstrated development of peria-
nastomotic varices in IPAA. A less favorable outcome 
in PSC-IBD after colectomy was suggested, however, 
by a more recent study in which one-third of the 
patients progressed to OLT or death within an mean 
of 2.6 years[94]. In addition, this study stressed the 
importance of pre-operative assessment of liver 
function, finding a low preoperative platelet count and 
a low albumin level to be related to worse outcomes.
A frequently reported long term complication of 
IPAA in both IBD and PSC-IBD is pouchitis. Symptoms 
of pouchitis reported in the included studies are 
(bloody) diarrhea, abdominal cramping, urgency, 
malaise, and fever[95,96]. The definitions and diagnostic 
criteria for pouchitis however differed substantially 
between studies, making comparisons difficult. For 
instance, most authors found increased overall rates 
of pouchitis in PSC-UC, while Gorgun et al[71], who only 
looked at chronic pouchitis, found lower rates (13.8%) 
that were comparable to UC controls. Based on the 
included studies, we found that approximately 60% 
of PSC-UC patients experienced at least one episode 
of pouchitis after proctocolectomy with IPAA. This 
is more frequent when compared with conventional 
IBD after IPAA where pouchitis is observed in 
approximately one-third of the patients. Chronic 
pouchitis after IPAA is observed less frequently, but it 
still occurred more often in PSC-IBD when compared 
to IBD without PSC. Although pouchitis was found 
more common in PSC-IBD after IPAA, the rate of 
pouch failure does not seem to be increased and is 
comparable to IBD without PSC.
From a molecular perspective there is also in-
creasing evidence that PSC-IBD is distinct from 
UC and CD. Large scale genetic studies performed 
within the International IBD Genetics Consortium 
have identified 163 independent genetic loci to be 
associated with IBD. The majority of these loci are 
shared between both UC and CD[97]. Similar studies 
have been performed within the International PSC 
study group, and they identified 16 independent loci 
outside the HLA region[98]. mathematical modeling of 
these genetic variants showed that PSC is genetically 
more similar to UC than to CD which is comparable 
to the clinical observation. A striking finding of these 
studies is that only 50% of the PSC risk loci are 
shared with IBD. Based on power calculations and 
the fact that more than 70 % of the PSC patients had 
concomitant IBD one would have expected that many 
more of the 163 IBD loci would be associated with 
PSC than is currently observed[98,99]. These intriguing 
findings suggest that from a genetic perspective IBD-
PSC is different from both CD and UC. 
Based on our findings, several recommendations 
can be made concerning futures studies and the 
management of IBD associated with PSC. 
Large differences between IBD rates in PSC were 
found. Therefore, to accurately assess or exclude 
the presence of IBD in PSC, a full colonoscopy with 
multiple biopsies from every segment and terminal 
ileum is required. Furthermore, the additional 
diagnostic criteria and a uniform definition are needed 
to assess the actual presence of backwash ileitis and 
rectal sparing in PSC-IBD patients.
Studies on the risk of the development of colonic 
neoplasia in PSC-IBD would benefit from a standard 
statistical outcome allowing comparison. The increase 
in the development of large bowel neoplasia in PSC-
IBD patients observed in these studies requires 
frequent surveillance colonoscopy. The optimal timing 
of the start of surveillance warrants further study as 
recent data were found to be contradictory.
The use of cyclosporin A and azathioprine in-
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stead of tacrolimus should be considered after liver 
transplantation for PSC, as the former were associated 
with a lower rate of IBD exacerbation and the deve-
lopment of de novo disease. 
The safety and outcome of proctocolectomy in 
PSC-IBD depend upon the severity of liver disease, 
something which should always be assessed pre-
operatively. Ileal pouch-anal anastomosis recon-
struction after colectomy in PSC-IBD was associated 
with a frequent development of pouchitis, and 
patients should be informed about this risk. Choosing 
for IPAA instead of ileostomy in PSC-IBD, however, 
seems favorable as the risk of development of local 
perianastomotic varices is low.
In conclusion, although IBD in PSC is common, 
there is a large variance in observed rates, which 
seems to be related to case ascertainment and, 
possibly, geographical variance. Based on the described 
clinical characteristics, the higher risk of development 
of colonic neoplasia, and the increasing molecular 
evidence, PSC-IBD should be regarded as a distinct 
phenotype of IBD, which differs from UC and CD and 
which therefore requires specialized management.
COMMENTS
Background
Inflammatory bowel disease (IBD) in Primary sclerosing cholangitis (PSC) often 
presents as quiescent disease affecting the whole colon. It is reported to be 
associated with backwash ileitis and rectal sparing. In addition an increased 
risk for the development of colorectal carcinoma has been described in several 
studies.
research frontiers
Based on differences in disease characteristics it has been suggested that IBD 
in PSC represents a distinct phenotype in addition to ulcerative colitis (UC) 
and Crohn’s disease. Studies looking at the characteristics for this phenotype 
however are limited.
Innovations and breakthroughs
While previous studies have summarized different aspects of IBD in PSC, 
studies providing a description of the PSC-IBD phenotype are limited. By 
reviewing existing literature on five relevant subthemes, an overview of the 
characteristics of the PSC-IBD phenotype is provided. 
Applications
The results of this study suggest that IBD in PSC is different from conventional 
IBD and therefore represents a distinct phenotype which requires specialized 
management. 
Terminology
PSC is a chronic cholestatic liver disease characterized by inflammation and 
fibrosis of both the intrahepatic and extrahepatic bile ducts. There is no curative 
therapy available and in most cases, PSC leads to liver cirrhosis and liver 
failure ultimately requiring liver transplantation. In the majority of cases PSC is 
accompanied by IBD most often UC. 
Peer-review
The authors provided a systemic review on PSC-IBD characteristics compare 
to UC and IBD. The review is interesting and well done.
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